Immune Checkpoint Inhibitor Market

Immune Checkpoint Inhibitors Market Insight (2022-2031)

The global immune checkpoint inhibitors market size was valued at $34,923.36 Million in 2021 and is projected to reach $1,55,193.28 Million by 2031, registering a CAGR of 16.1% from 2022 to 2031.

COVID-19 Banner Statement: The immune checkpoint inhibitors market was negatively impacted by the COVID-19 pandemic. Owing to decline in the number of cancer patient visits in hospitals and clinics for immune checkpoint inhibitor therapies lead to a decline in the demand for immune checkpoint inhibitor products. For instance, according to AstraZeneca Plc, Opidivo (immune checkpoint inhibitor) registered a decline in revenue.

Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body. Immune checkpoints engage when proteins on the surface of immune cells called T cells recognize and bind to partner proteins in other cells, such as some tumor cells. These proteins are called immune checkpoint proteins. When the checkpoint and partner proteins bind together, they send an “off” signal to the T cells. This can prevent the immune system from destroying cancer. Immunotherapy drugs called immune checkpoint inhibitors to work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.

“The global immune checkpoint inhibitors market was slightly decreased during the lockdown period owing to a decline in the number of cancer patient visits in hospitals & clinics for immune checkpoint inhibitor therapy (ICI), which lead to a decline in demand for immune checkpoint inhibitor products during covid-19”

Historical Overview

The market was analyzed qualitatively and quantitatively from 2018-2020. Most of the growth during this period was derived from the Asia-Pacific owing to the improving health awareness, rising disposable incomes, as well as the well-established presence of domestic companies in the region.   

Market Dynamics

Growth & innovations in the pharmaceutical industry for cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to a better understanding of the disease pathophysiology, the functioning of the tumor cells, and effective ways to tackle the rising cancer rate creates an opportunity for the immune checkpoint inhibitors market. A rise in the number of R&D activities by various key players across the globe and increasing approval of the immune checkpoint inhibitors by the regulatory bodies are expected to drive the global immune checkpoint market over the forecast period and are set to affect the market growth positively.

For instance, in August 2021, GSK plc., a Pharmaceutical and Biotechnology Company, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The growth of the immune checkpoint inhibitors market is expected to be driven by the high potential in untapped, emerging markets, due to the availability of improved healthcare infrastructure, an increase in unmet healthcare needs, a rise in the prevalence of cancer and chronic diseases, and surge in demand for ideal therapeutics for the treatment of cancer.

The healthcare industry in emerging economies is developing at a significant rate, owing to the rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructure, and the increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs are the factors propelling the market growth. The demand for immune checkpoint inhibitors is not only limited to developed countries but is also being witnessed in developing countries, such as China, Brazil, and India, which fuel the growth of the market. Factors such as the growing geriatric population and rise in the technological advancements in screening & diagnosis of cancer further drive the market growth.

What is the impact of COVID-19 on Immune Checkpoint Inhibitors Market?

The high cost of immuno-oncology therapies, which is unaffordable to low and middle-income populations is anticipated to hamper the growth of the market.

The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The global immune checkpoint inhibitors market experienced a decline in 2020 due to the global economic recession led by COVID-19. In addition, the COVID-19 outbreak disrupted the supply chain across various end-user industries like food & beverage, healthcare, and industrial. However, the market is anticipated to witness recovery in 2021, and show stable growth for the immune checkpoint inhibitors market in the coming future. This is attributed to the increase in the prevalence of cancer and chronic disease as well as an increase in demand for novel drug therapies for the treatment of cancer.   |

Segmental Overview

The global immune checkpoint inhibitors market is segmented on the basis of type, application, and region. By type, the market is classified as a PD-1 inhibitor, PD-L1 inhibitor, and CTLA-4 inhibitor. According to the application, it is categorized into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By type: based on type, the market is segmented into a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. The PD-1 inhibitor segment was the major revenue contributor in 2021 and is anticipated to continue this trend during the forecast period, owing to an increase in the adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. On the other side, the demand for PD-L1 inhibitors is projected to exhibit the fastest market growth during the forecast period, owing to the rise in the use of durvalumab & avelumab and the surge in R&D studies for PD-L1 inhibitors.  

By application: immune checkpoint inhibitors market is segregated into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, and others. The lung cancer segment presently dominates the market and is expected to remain dominant during the forecast period, owing to an increase in the use of immune checkpoint inhibitors for the treatment of lung cancer and a surge in the prevalence of lung cancer globally. However, the colorectal cancer segment is projected to show the fastest growth during the forecast period, owing to an increase in incidences of colorectal cancer.  

By region: The immune checkpoint inhibitors market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.  North America accounted for a major share of the immune checkpoint inhibitors market in 2021 and is expected to maintain its dominance during the forecast period.

The surge in the use of immune checkpoint inhibitors, owing to the presence of advanced healthcare facilities and a higher number of the target population. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to developments in healthcare infrastructure with the rise in demand for immune checkpoint inhibitors market.

The Asia-Pacific region exhibits the largest medicine supply and the largest pharmaceutical industry with the availability of raw materials in abundance. This, in turn, drives the growth of the market. Asia-Pacific offers profitable opportunities for key players operating in the immune checkpoint inhibitors market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as the well-established presence of domestic companies in the region. In addition, the rise in contract manufacturing organizations within the region provides a great opportunity for new entrants in this region.  

Competition Analysis

Competitive analysis and profiles of the major players in the immune checkpoint inhibitors market, such as AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Sanofi, Merck & Co., Inc., Merck KGaA, and BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd. are provided in this report. Major players have adopted product launch, product expansion, and acquisition as key developmental strategies to improve the product portfolio of the immune checkpoint inhibitors market.  

Some examples of product launches in the market

GlaxoSmithKline, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, recently got the U.S. Food and Drug Administration (FDA) approval for PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

Furthermore, on April 06, 2022, the Food and Drug Administration (FDA) approved a combination of two immunotherapy drugs for the treatment of some people with advanced melanoma. The combination consists of relatlimab and nivolumab (Opdivo) and will be marketed under the name Opdualag. Both drugs are immune checkpoint inhibitors, which target proteins called checkpoints that help stop the immune system from mounting a strong response against cancer cells. Relatlimab blocks a protein in immune cells called LAG-3, while nivolumab blocks a different protein in immune cells called PD-1. By blocking these proteins, these drugs can unleash an immune response against cancer cells. Relatlimab is the first FDA-approved drug to block the activity of LAG-3.

 Immune Checkpoint Inhibitor Market Report Highlights